Selected outcome
a full approval or an accelerated approval
50%
a full approval or an accelerated approval · 50%
Stored quote · checking the venue
- Scheduled end
- Dec 31, 2026 ET
- Resolution source
- AppliedXL (opens in a new tab)
Price
a full approval or an accelerated approval
Loading price history.
Markets
- a full approval or an accelerated approval
What will the FDA's decision be on Ivonescimab by Summit Therapeutics in 2026?
50%
Open · ~$15 24h · ~$4,868 vol
Bid 47¢ · Ask 52¢
Event statistics
How this resolves
One winner.
- Scheduled end
- Dec 31, 2026 ET
- Resolution source
- Trading
- Closed
- In review
- Resolved
Rules text
If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.